A Study to Assess Anktiva in Patients With Long Covid-19. (INTERRUPT_LC)

Mij

Mij

Senior Member (Voting Rights)
Official Title
Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid

Brief Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.

Study Contact
Name: Kamin Personett

Phone Number: 12673777737

Email: kamin.personett@immunitybio.com

California Locations
San Francisco, California, United States, 94110

University of California - San Francisco
Contact :
Emily Fehrman
(650) 761-2163 Emily.Fehrman2@ucsf.edu
Principal Investigator :
Michael Peluso, MD
 
A new PostCOVID/LongCOVID single-arm study by ImmunityBio of Anktiva, an interleukin-15 receptor agonist which is used to treat bladder cancer.

20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.
 
ImmunityBio

Dr. Patrick Soon-Shiong
By 1990, we recognized that the key immune cell type involved in organ rejection following transplantation and in killing cancer cells was the natural killer (NK) cell – ‘nature’s first responder’. The isolation of the NK cells by Dr. Hans Klingemann in 1992 that became the NK-92 cell line, set us on our current course of developing NK cell-based therapies for the treatment of cancer and infectious disease.
 
July 31, 2025

Just out in Nature yesterday, SARS-COv-2 infection can awaken sleeping cancer cells! My concern mounts with increasing evidence that COVID is a cancer inducing virus. Viral clearance is more important than ever, especially in those with LONG-COVID.
 

Anktiva boosts NK cells.​

How ANKTIVA Works:
  • IL-15 Agonist:
    ANKTIVA is a fusion protein that mimics the action of interleukin-15 (IL-15), a cytokine that stimulates immune cells.

  • Activates NK Cells:
    It enhances the activity and proliferation of NK cells, which are part of the innate immune system and play a key role in eliminating cancer cells.

 
From the link above:

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.
 
Intravesical therapy for bladder cancer. The doctor puts a liquid drug right into your bladder rather than giving it by mouth or putting it into your blood. The drug is given through a tube (urinary catheter) that's been put into your bladder through your urethra.
 
@Jaybee00

I found this

The primary objective of the exploratory, single-arm study (NCT07123727) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA’s ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells.

ClinicalTrials.gov

clinicaltrials.gov clinicaltrials.gov

600ug of NAI administered subcutaneously
 
You must log in or register to reply here.
Back
Top Bottom